Abstract Treatment with statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A
reductase, has proven beneficial preventive effects on cardiovascular events. However …

The pharmacological treatment of dyslipidemia, a major modifiable risk factor for developing
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …

Moreover, over the last few years the approach to treatment of patients with a high
cardiovascular risk has totally changed from treatment aimed at a specific risk factor (ie …

Cardiovascular disease (CVD) is a chronic non-communicable disease (NCD) and the
predominant cause of morbidity and mortality worldwide. Substantial reductions in the CVD …

As dyslipidemias remain one of the main risk factors for developing cardiovascular disease,
the question of maintaining optimal lipid levels with pharmacotherapy remains a subject of …

Among patients presenting with acute myocardial infarction (AMI), the proportion of young
individuals has increased in recent years. Although coronary atherosclerosis is less …

Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with
statin therapy [most commonly statin‐associated muscle symptoms (SAMS)] result in the …

Background We aimed to compare statin monotherapy and upfront combination therapy of
statin and ezetimibe in patients with acute coronary syndromes (ACSs). Methods and …

We live in interesting times, when we finally have the possibility of effective treatment of
patients with lipid disorders, and in fact with numerous effective drugs available, it should be …

Dyslipidemia is a fundamental risk factor for cardiovascular diseases (CVDs) and can
worsen the prognosis, if unaddressed. Lipid guidelines are still evolving as dyslipidemia is …